XOMA Royalty Corp Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Income from purchased receivables under the EIR method
Adjustment for income from EIR method purchased receivables
Stock-based compensation expense
Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs
Credit losses on purchased receivables
Impairment charges
Gain on sale of equity securities
Income tax expense (benefit)
Common stock contribution to 401(k)
Amortization of intangible assets
Depreciation
Accretion of long-term debt discount and debt issuance costs
Loss on extinguishment of debt
Reduction of contingent NIH refund liability
Non-cash lease expense
Change in fair value of equity securities
Change in fair value of available-for-sale debt securities classified as cash equivalents
Change in fair value of derivatives
CVR liability working capital adjustment
Changes in assets and liabilities:
Trade and other receivables, net
Income tax receivable
Prepaid expenses and other assets
Accounts payable and accrued liabilities
Income taxes payable
Operating lease liabilities
Unearned revenue recognized under units-of-revenue method
Contingent NIH refund liability
Other liabilities

Net cash provided by (used in) operating activities
Cash flows from investing activities:
Net cash acquired in acquisition
Turnstone
Kinnate
Total net cash acquired in acquisition
Net cash and restricted cash acquired in acquisition
HilleVax
LAVA
Mural
Payments of consideration under RPAs, AAAs, and CPPAs
Receipts under RPAs, AAAs, and CPPAs
Net payment for IP acquired under the Pulmokine Acquisition
Payment for BioInvent contract-based intangible asset
Payment of contingent consideration related to Kinnate IP asset
Receipts under RPAs and CPPAs
Payments related to purchase of royalty rights and other commercial payment rights
Purchase of property and equipment
Purchase of equity securities
Sale of equity securities
Payment to issue short-term loan to Xeno
Receipt from short-term loan repayment by Xeno
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from issuance of common stock
Proceeds from issuance of preferred stock
Payment of preferred and common stock issuance costs
Payments of preferred and common stock issuance and financing costs
Proceeds from issuance of long-term debt
Principal payments - debt
Debt issuance costs and loan fees paid in connection with long-term debt
Payment of preferred stock dividends
Repurchases of common stock
Proceeds from exercise of options and other share-based compensation
Taxes paid related to net share settlement of equity awards
Other
Payment for extinguishment of debt
Payment for debt modification fee
Net cash used in financing activities

Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash as of the beginning of the period
Cash, cash equivalents, and restricted cash as of the end of the period
Supplemental cash flow information:
Cash paid for interest
Right-of-use assets obtained in exchange for operating lease liabilities
Cash paid for taxes
Non-cash investing and financing activities:
Estimated fair value of contingent consideration under the Affitech CPPA
Issuance of common stock warrants in connection with long-term debt
Accrued issuance costs in connection with issuance of long-term debt
Estimated initial fair value of contingent consideration under the LadRx Agreement
Accrued transaction costs in connection with ObsEva IP Acquisition
Accrual of contingent value rights liability in the acquisition
Turnstone
HilleVax
LAVA
Right-of-use assets obtained in exchange for operating lease liabilities in the acquisition
HilleVax
Kinnate
Total right-of-use assets obtained in exchange for operating lease liabilities in the acquisition
Relative fair value basis reduction of rights-of-use assets in the acquisition
HilleVax
Kinnate
Total relative fair value basis reduction of rights-of-use assets in the acquisition
Transaction costs in connection with acquisition included in accrued expenses
Excise tax accrual due to stock repurchases
Reclassification of equity classified awards to liabilities
Reclassification of deferred issuance cost to equity
Preferred stock dividend accrual
Estimated fair value of the Exarafenib milestone asset
Estimated fair value of the Exarafenib milestone contingent consideration
Accrual of contingent consideration under the Affitech CPPA
Accrual of contingent consideration under the LadRx AAA

Comments